The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Open accessAbstract
Cerebrospinal fluid (CSF) tau (total tau, T-tau), neurofilament light (NFL), and neurogranin (Ng) are potential biomarkers for neurodegeneration in Alzheimer's disease (AD). It is unknown whether these biomarkers provide similar or complementary information in AD. We examined 93 patients with AD, 187 patients with mild cognitive impairment, and 109 controls. T-tau, Ng, and NFL were all predictors of AD diagnosis. Combinations improved the diagnostic accuracy (AUC 85.5% for T-tau, Ng, and NFL) compared to individual biomarkers (T-tau 80.8%; Ng 71.4%; NFL 77.7%). T-tau and Ng were highly correlated (ρ = 0.79, P < 0.001) and strongly associated with β-amyloid (Aβ) pathology, and with longitudinal deterioration in cognition and brain structure, primarily in people with Aβ pathology. NFL on the other hand was not associated with Aβ pathology and was associated with cognitive decline and brain atrophy independent of Aβ. T-tau, Ng, and NFL provide partly independent information about neuronal injury and may be combined to improve the diagnostic accuracy for AD. T-tau and Ng reflect Aβ-dependent neurodegeneration, while NFL reflects neurodegeneration independently of Aβ pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“CSF total tau (T-tau) is a well-studied biomarker, which is increased in neuronal degeneration (Blennow et al, 2006) and in AD patients already in early clinical stages (Mattsson et al, 2009; Albert et al, 2011; McKhann et al, 2011; Sperling et al, 2011; Dubois et al, 2014).”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citationAlzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2007) · Advances in Behavioral Biology · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,468
Self-citationCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Self-citationAmyloid deposition, hypometabolism, and longitudinal cognitive decline
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J., & Initiative, F. T. A. D. N. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 727
Self-citationAlzheimer' Disease as a Disconnection Syndrome?
Delbeuck, X., Van der Linden, M., & Collette, F. (2003) · Neuropsychology Review · doi:10.1023/a:1023832305702 · Cited by 682
Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · cited 3×
“But CSF NFL is also relevant in AD (Zetterberg et al, 2016) since AD not only involves loss of cortical structures but also white matter injury (Migliaccio et al, 2012) and disconnection of cortical and subcortical regions (Delbeuck et al, 2003).”
Self-citationHall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473
Self-citationKvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 340
Self-citationCerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Self-citationCSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · cited 1×
“…et al, 2013), Creutzfeldt-Jakob disease (van Eijk et al, 2010), acute neuronal ischemia (Merisson et al, 2016), subcortical vascular dementia (Skillbäck et al, 2014), atypical parkinsonian disorders (Hall et al, 2012), and frontotemporal lobe dementia (FTD) (Petzold et al, 2007; Pijnenburg…”
Self-citationScherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246
Increased CSF neurogranin concentration is specific to Alzheimer disease
Wellington, H., Paterson, R. W., Portelius, E., Törnqvist, U., Magdalinou, N., Fox, N. C., Blennow, K., Schott, J. M., & Zetterberg, H. (2016) · Neurology · doi:10.1212/wnl.0000000000002423 · Cited by 232
Self-citationDiagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Tarawneh, R., D’Angelo, G., Crimmins, D., Herries, E., Griest, T., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 215
RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes
Gerendasy, D. D., & Gregor Sutcliffe, J. (1997) · Molecular Neurobiology · doi:10.1007/bf02740632 · Cited by 212
Neurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Self-citationCerebrospinal fluid neurogranin and YKL ‐40 as biomarkers of Alzheimer's disease
Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldö, M., Santillo, A., Blennow, K., & Hansson, O. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.266 · Cited by 179
Self-citationNeurofilament protein levels in CSF are increased in dementia
Rosengren, L., Karlsson, J. E., Sjögren, M. J. C., Blennow, K., & Wallin, A. (1999) · Neurology · doi:10.1212/wnl.52.5.1090 · Cited by 160
Self-citationHellwig, K., Kvartsberg, H., Portelius, E., Andréasson, U., Oberstein, T. J., Lewczuk, P., Blennow, K., Kornhuber, J., Maler, J. M., Zetterberg, H., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0161-y · Cited by 151
Self-citationCerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127
Self-citationCSF neurofilament proteins in the differential diagnosis of dementia
de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107326 · Cited by 120 · cited 1×
“More work is needed to scrutinize CSF NFL in biomarker algorithms for differential diagnostics (de Jong et al, 2007).”
A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
Petzold, A., Keir, G., Warren, J. D., Fox, N. C., & Rossor, M. N. (2007) · Neurodegenerative Diseases · doi:10.1159/000101843 · Cited by 119
Hu, Y., Shanshu, H., Wang, X., Duan, Q., Khatoon, S., Iqbal, K., Grundke, I., & Wang, J. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00047-2 · Cited by 115
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 113
Self-citationSchwarz, C. G., Fletcher, E., DeCarli, C. S., & Carmichael, O. T. (2009) · Lecture notes in computer science · doi:10.1007/978-3-642-02498-6_20 · Cited by 104
CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis
Christensen, J. R., Börnsen, L. S., Khademi, M., Olsson, T. P., Jensen, P. E., Sørensen, P. S., & Sellebjerg, F. T. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512466929 · Cited by 98
White matter atrophy in Alzheimer's disease variants
Migliaccio, R., Agosta, F., Possin, K. L., Rabinovici, G. D., Miller, B. L., & Gorno‐Tempini, M. L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.04.010 · Cited by 95
Pijnenburg, Y. A. L., Janssen, J. C., Schoonenboom, N. S. M., Petzold, A., Mulder, C., Stigbrand, T. I., Norgren, N., Heijst, H., Hack, C. E., Scheltens, P., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000099473 · Cited by 88
Emerging β-amyloid pathology and accelerated cortical atrophy
Mattsson, N., Insel, P. S., Nosheny, R., Tosun, D., Trojanowski, J. Q., Shaw, L. M., Jack, C. R., Donohue, M. C., & Weiner, M. W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.446 · Cited by 71
Self-citationNeuroinflammation in Lyme neuroborreliosis affects amyloid metabolism
Mattsson, N., Bremell, D., Anckarsäter, R., Blennow, K., Anckarsäter, H. S., Zetterberg, H., & Hagberg, L. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-51 · Cited by 64
Self-citationThe transitional association between β‐amyloid pathology and regional brain atrophy
Insel, P. S., Mattsson, N., Donohue, M., Mackin, R. S., Aisen, P. S. S., Jack, C. R., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.11.002 · Cited by 56
Self-citationAccelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology
Insel, P. S., Mattsson, N., Mackin, R. S., Schöll, M., Nosheny, R. L., Tosun, D., Donohue, M., Aisen, P. S. S., Jagust, W., Weiner, M. W., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002683 · Cited by 53
Self-citationCSF Neurofilament Proteins Levels are Elevated in Sporadic Creutzfeldt-Jakob Disease
van Eijk, J. J. J., Everbroeck, B. V., Abdo, W. F., Kremer, B. P. H., & Verbeek, M. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-090649 · Cited by 46
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Self-citationMerisson, E., Mattsson, N., Zetterberg, H., Blennow, K., Pikwer, A., Mehmedagic, I., Acosta, S., & Åkeson, J. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.12.003 · Cited by 17
Self-citation
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationNeurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Self-citationAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Self-citationJohnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citation
Metadata
- Authors
- Mattsson, N., Insel, P. S., Palmqvist, S., Portelius, E., Zetterberg, H., Weiner, M., Blennow, K., Hansson, O., & Initiative, T. A. D. N.
- Venue
- EMBO Molecular Medicine
- Published
- 2016-08-17
- Volume
- 8
- Issue
- 10
- Pages
- 1184-1196
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2518545320
- Cited by
- 294
- References
- 44
- FWCI
- 19.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.